Estriol monitoring of maternal blood for antenatal steroid acceleration
of fetal lung maturation
    2.
    发明授权
    Estriol monitoring of maternal blood for antenatal steroid acceleration of fetal lung maturation 失效
    雌三醇监测产妇血液产前类固醇加速胎儿肺成熟

    公开(公告)号:US5980470A

    公开(公告)日:1999-11-09

    申请号:US30905

    申请日:1998-02-26

    申请人: John S. Torday

    发明人: John S. Torday

    IPC分类号: G01N33/49 G01N33/74 A61B5/00

    摘要: Maternal blood unconjugated estriol is used to determine whether steroid treatment has or has not effectively accelerated fetal lung maturation and reduced the risk of RDS. A blood sample is obtained from the mother prior to treating her with steroids and again 24 hours later. The blood cells are separated from the serum and the serum is analyzed for unconjugated estriol concentration in the two blood samples obtained. If the percent change in the estriol concentration of the mother's blood decreases by a significant percentage over the 24 hour period from the start of the steroid treatment, the infant will not develop RDS. If the percent change in the estriol concentration of the mother's blood does not decrease by a significant percentage over the 24 hour period from the start of the steroid treatment, the infant will be at the same risk of RDS as it would have been without the steroid treatment. The information obtained from this test is used to make decisions regarding further treatment.

    摘要翻译: 产妇血液中未结合的雌三醇用于确定类固醇治疗是否有效加速了胎儿肺成熟,降低了RDS的风险。 在用类固醇治疗之前和24小时后再从母亲获得血样。 从血清中分离出血细胞,分析血清中获得的两个血液样品中的非共轭三醇浓度。 如果母体血液中雌二醇浓度的百分比变化在类固醇治疗开始后的24小时内降低显着百分比,则婴儿不会发展RDS。 如果母体血液中雌二醇浓度的百分比变化在类固醇治疗开始后的24小时内没有降低显着的百分比,那么婴儿将面临与没有类固醇相同的RDS风险 治疗。 从该测试获得的信息用于作出关于进一步治疗的决定。

    TARGETING PULMONARY EPITHELIUM USING ADRP
    6.
    发明申请
    TARGETING PULMONARY EPITHELIUM USING ADRP 审中-公开
    使用ADRP靶向脉管上皮

    公开(公告)号:US20120027675A1

    公开(公告)日:2012-02-02

    申请号:US13276204

    申请日:2011-10-18

    摘要: This invention provides novel compositions and methods for the specific and/or preferential delivery of an effector (e.g. a drug or label) to an epithelial cell (e.g. a pulmonary epithelium). The compositions comprise an adipocyte differentiation-related protein (ADRP) attached to an effector thereby forming a chimeric moiety. The chimeric moiety is preferentially delivered to epithelial cells.

    摘要翻译: 本发明提供了用于特异性和/或优先递送至上皮细胞(例如肺上皮)的效应物(例如药物或标记物)的新型组合物和方法。 组合物包含与效应物连接的脂肪细胞分化相关蛋白(ADRP),从而形成嵌合部分。 嵌合部分优先递送至上皮细胞。